Related Experiment Video
Updated: Jun 23, 2026

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care
Published on: February 16, 2015
The safety of temozolomide in the treatment of malignancies
Van Anh Trinh1, Sapna Pradyuman Patel, Wen-Jen Hwu
11University of Texas M.D. Anderson Cancer Center, Department of Melanoma Medical Oncology, 1515 Holcombe Boulevard, Box 0377, Houston, TX 77030, USA.
Background:
Temozolomide (TMZ) has demonstrated clinical antitumor activity. In the US and the EU, TMZ is licensed for the treatment of glioblastoma multiforme concurrently with radiation followed by a maintenance treatment, and for refractory anaplastic astrocytoma or glioblastoma multiforme. TMZ is also approved for metastatic melanoma in > 20 countries worldwide.
Objectives:
To ascertain the safety profile of TMZ.
Methods:
Synthesis of evidence from published clinical trials and the investigator's brochure of the manufacture.
Conclusion:
For a cytotoxic cancer-treatment agent, TMZ has an acceptable safety profile. Lymphopenia is common in patients treated with all doses and schedules of TMZ. All patients receiving TMZ should be observed for lymphopenia and potential opportunistic infections, particularly when it is combined with other immune suppressive therapies.
Related Concept Videos
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Treatment Resistent Cancers
Treatment Resistant Cancers
Drugs that Destabilize Microtubules

